Australian Patent Application

The use of pituitary adenylate cyclase-activating polypeptide PACAP and PACAP analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin mTOR complexes

Source-linked patent metadata for The use of pituitary adenylate cyclase-activating polypeptide PACAP and PACAP analogs as adjunctive treatments with inhibitors of calcineurin or inhibitors of the mammalian target of rapamycin mTOR complexes, including priority, record stage and longevity-topic connections.

Australian application snapshot

Patent application record

This privacy-minimal view describes one official Australian patent application record. It is not presented as a complete worldwide patent family.

Application number
AU2011213649
Earliest priority
February 5, 2010
Application date
August 1, 2012
Source record
1
Patent offices
1
Patent-to-Evidence Translation Map

What is happening in the same scientific field?

These connections share a longevity topic with this patent record. They do not prove that the listed evidence, trials, funders, or universities validate, finance, own, or support this invention.

Organizations

Why names are absent

This feed intentionally excludes party names and contact details to minimise personal data. Open the official record when a name is consequential.

Longevity context

Topics connected by metadata

Rapamycin82% metadata match
Technical classification

How the patent office classifies this invention

A61K38/13 · A61K38/16 · A61K38/17 · A61P25/00 · A61P35/00 · A61P37/00

Verify in the original patent source →